Skip to content
OpenCapital
Get started
InMed Pharmaceuticals logo

InMed Pharmaceuticals (INM) Q1 2026 Earnings

INM·Reported May 6, 2026·Before market open

InMed Pharmaceuticals reported Q1 2026 revenue of $1.3M (-29.8% YoY), missed analyst consensus of $659.8M by $658.6M. Diluted EPS came in at $-0.69 (+64.4% YoY), beat the $-94.44 consensus by $93.75.

Revenue
$1.3Mmissed by $658.6M
Consensus: $659.8M
Diluted EPS
$-0.69beat by $93.75
Consensus: $-94.44
SEC

SEC Filings

Earnings release8-K · 0001062993-26-002371
Quarterly report10-Q · 0001213900-26-052920

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about InMed Pharmaceuticals's Q1 2026 earnings report.

InMed Pharmaceuticals (INM) reported Q1 2026 earnings on May 6, 2026 before market open.

InMed Pharmaceuticals reported revenue of $1.3M and diluted EPS of $-0.69 for Q1 2026.

Revenue missed the consensus estimate of $659.8M by $658.6M. EPS beat the consensus estimate of $-94.44 by $93.75.

Compared to the same quarter a year prior, revenue declined 29.8% from $1.8M a year earlier and diluted EPS grew 64.4% from $-1.94.

You can read the 8-K earnings release (0001062993-26-002371) and the 10-Q periodic report (0001213900-26-052920) directly on SEC EDGAR. The filing index links above go to sec.gov.